What this Trial Is About

This research is a pilot, observational, retrospective study conducted across multiple centers in Italy. It focuses on patients with relapsed or refractory Diffuse Large B Cell Lymphoma (DLBCL) who have been treated with a combination of tafasitamab and lenalidomide. The purpose is to assess the effectiveness and safety of this treatment combination as used in real-world clinical practice under the Named Patient Program (NPP). The study collects patient data from medical records of those who received at least one dose of tafasitamab with lenalidomide between April 2022 and December 2022. Since this is a non-interventional study, no additional treatments or procedures are applied beyond what is normally done in clinical care. The treatment details and outcomes reflect standard care settings without extra interventions for the study. Participants will not undergo any procedures outside their usual care. Researchers will gather clinical variables that are typically recorded during routine practice to evaluate outcomes. The main outcome measured is the overall response rate (ORR) to the treatment combination, tracked through study completion, averaging about two years. The study monitors effectiveness and safety by reviewing existing health records without additional patient visits or tests.

An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program